Daiichi Sankyo: Pipeline * Products * Performance * Potential

Published by	Espicom Business Intelligence
Published	October, 2009	Product code	42293
Content info	Pages: 98
Price	US $ 1040 Hard Copy US $ 1040 PDF by E-mail (Single user license) US $ 1040 Web Access (Single user license)

Introduction
Related Reports

Daiichi Sankyo: Pipeline * Products * Performance * Potential published by Espicom Business Intelligence in October, 2009. This report consists of Pages: 98 and the price starts from US $ 1040.

Introduction

Abstract

Daiichi Sankyo's core strategy is to become a Japanese "Global Pharma Innovator". This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

For the nine months ended 31st December 2005, Daiichi Sankyo's net sales were ¥704,039 million. Operating income was ¥134,294 million and net income was ¥80,992 million. Research and development expenditure was ¥113,371 million and pharmaceutical sales were ¥606,349 million.

Key products

Daiichi Sankyo intends to maximise the value of its existing leading products, beyond what could have been achieved by the companies separately. For example:

Daiichi Sankyo is undertaking life-cycle management of the antihypertensive, Olmetec/Benicar, which is one of the companies main growth drivers. Since its introduction in a number of markets, sales and market share are increasing.
The future growth of the anti-infective Cravit is expected to be strong due to life-cycle management efforts.
In fiscal 2005, sales of the antihypertensive, Calblock, increased by 400%, to reach ¥3,000 million and are forecast to exceed ¥10 billion in Japan.

Overseas pharmaceutical sales were negatively affected by the expiration of the patent in certain European countries for pravastatin and increasing competition faced by that product in the US, which weakened sales of bulk pravastatin. However, sales of olmesartan and levofloxacin were strong.

Major Products Forecast to 2010

Cravit (Antibacterial)
Omnipaque (Contrast agent)
Panaldine (Cardiovascular)
Artist (Cardiovascular)
Sunrythm (Cardiovascular)
Zyrtec (Anti-inflammatory)
Mevalotin (Cardiovascular)
Loxonin (Anti-infective)
Remacin (Haematological)
Acecol (Cardiovascular)
Banan (Antibacterial)
Espo (Haematological)
Carbenin (Antibacterial)
Gran (Anticancer)
Alesion (Anti-allergenic)
Olmetec (Cardiovascular)

EXECUTIVE SUMMARY

Introduction
Financial Performance 2005
- Sales and Market Position
- Income
  - Operating Income By Business Area - Daiichi
  - Operating Income by Business Area - Daiichi
  - Operating Income By Business Area - Sankyo
  - Operating Income by Business Area - Sankyo
- Expenditure
  - Capital Expenditure
  - Capital Expenditure By Business Area - Daiichi
  - Capital Expenditure by Business Area - Daiichi
  - Capital Expenditure By Business Area - Sankyo
  - Capital Expenditure by Business Area - Sankyo
  - R&D Expenditure
- Divisional Performance
  - Sales By Business Area - Daiichi
  - Sales By Business Area - Daiichi
  - Sales By Business Area - Sankyo
  - Sales by Business Area - Sankyo
  - Total Assets By Business Area - Daiichi
  - Total Assets By Business Area - Daiichi
  - Total Assets By Business Area - Sankyo
  - Total Assets by Business Area - Sankyo
- Geographic Performance
  - Sales By Destination - Sankyo
  - Sales by Destination - Sankyo
  - Sales By Origin - Daiichi
  - Sales By Origin - Daiichi
  - Sales By Origin - Sankyo
  - Sales By Origin - Sankyo
  - Operating Income By Geographical Area - Sankyo
  - Total Assets By Geographical Area - Sankyo
Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Employees
Product/R&D Overview
- Key Products
  - Recent Product Launches
  - Recent Product Approvals
  - Discontinued Products
- R&D Strategy
  - Key R&D Projects
- R&D Pipeline Overview
  - Discontinued R&D Projects
- Sales Forecast
  - Sales of Major Products (2000A-2010E)
Conclusions

PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT

Major Products, Therapeutic Areas and Sales
Top Selling Products, 2005
R&D Pipeline - Japan

Cardiovascular - Products
- Major Launched Products
- Acecol
  - Sales
  - Competitor Products
  - Sales Forecast
- Acecol Sales (2000A-2010E)
- Artist
  - Sales
  - Competitor Products
  - Sales Forecast
- Artist Sales (2000A-2010E)
- Calblock
  - Sales
- Coversyl (DW-7950)
  - Sales
  - Key Markets/Indications
  - Clinical Trial Results
- HANP Injection
- Livalo
  - Sales
- Mevalotin/Pravachol
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Generic Competition
  - Sales Forecast
- Mevalotin Sales (2000A-2010E)
- Olmetec/Benicar
  - Sales
  - Markets/Indications
  - Further Development
  - Competitor Products
  - Sales Forecast
- Olmetec/Benicar Sales (2000A-2010E)
  - Clinical Trial Results
- Panaldine
  - Sales
  - Safety Issues
  - Competitor Products
  - Sales Forecast
- Panaldine Sales (2000A-2010E)
- Sunrythm
  - Sales
  - Competitor Products
- WelChol
  - Sales
  - Key Markets/Indications
  - Further Development
  - Clinical Trial Results
Cardiovascular - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Adenoscan
- CS-3030
- DU-176b
- DZ-697b
- HGF DNA plasmid
- KAI-9803
- Prasugrel (CS-747, LY640315)
  - Clinical Trial Results
- SUN N4057
- SUN N8075
Cardiovascular - Summary
- Growth Potential
- Limiting Factors
Metabolism - Products
- Major Launched Products
- Fastic
  - Sales
  - Markets/Indications
  - Further Development
- Others
Metabolism - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-011
- CS-872
- CS-917 (R-132917)
  - Development Status
- Fidarestat (SNK-860)
- SUN E7001
Metabolism - Summary
- Growth Potential
- Limiting Factors
Infection - Products
- Major Launched Products
- Banan
  - Sales
  - Key Markets/Indications
  - Generic Competition
  - Sales Forecast
- Banan Sales (2000A-2010E)
- Carbenin
  - Sales
  - Sales Forecast
- Carbenin Sales (2000A-2010E)
- Cravit
  - Sales
  - Key Markets/Indications
  - Lawsuits/Generic Competition
  - Sales Forecast
- Cravit Sales (2000A-2010E)
Infection - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- Act-HIB (DF-098)
- CS-023
- CS-3955
- CS-758
- CS-8958 (R118958)
- DX-619
- Faropenem medoxomil
- Gracevit (DU-6859a)
Infection - Summary
- Growth Potential
- Limiting Factors
Cancer - Products
- Topotecin
  - Key Markets/Indications
  - Further Development
Cancer - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-706 (R-109339)
- CS-1008 (R-161460)
- CS-7017 (RS-5444)
- TZT-1027
- DJ-927
Cancer - Summary
Immunity and Allergy - Products
- Major Launched Products
- Alesion
  - Sales
  - Sales Forecast
- Alesion Sales (2000A-2010E)
- Zyrtec
  - Sales
  - Key Markets/Indications
  - Competitor Products
  - Sales Forecast
- Zyrtec Sales (2000A-2010E)
Immunity and Allergy - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-0777
- CS-502
- CS-712 (R-133663)
- CS-9507 (R-125224)
- DW-908e
- Xolair (omalizumab, IGE025)
Immunity and Allergy - Summary
- Growth Potential
- Limiting Factors
Bone and Joints - Products
- Major Launched Products
- Loxonin
  - Sales
  - Key Markets/Indications
  - Further Development
  - Competitor Products
  - Sales Forecast
- Loxonin Sales (2000A-2010E)
- Mobic
Bone and Joints - R&D
- R&D Pipeline - Japan
- OCIF (R-142440)
- SUN E3001
Bone and Joints - Summary
Other - Products
- Major Launched Products
- Feron
- Kremezin
  - Sales
- Omnipaque
  - Sales
  - Sales Forecast
- Omnipaque Sales (2000A-2010E)
- Zantac
  - Sales
  - Sales Forecast
- Zantac Sales (2000A-2010E)
Others - R&D
- R&D Pipeline - Japan
- R&D Pipeline - Overseas
- CS-088
- CS-526 (R-105266)
- CS-801
- CS-1401E
- Dopascan
- DL-404
- Sonazoid
- SUN11031
- SUN0588r
- SUN-Y7017
  - Clinical Trial Results
- Urief

APPENDIX 1 - FINANCIAL PERFORMANCE

Full Year Results - Proforma
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
Full Year Results 2005 - Daiichi
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- Research Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
Full Year Results 2005 - Sankyo
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity

APPENDIX 2 - KEY AGREEMENTS

A Menarini Industrie Farmaceutiche Riunte SrL
- 16th March 2001
Amersham Health
- 19th March 1998
AnGes MG Inc
- January 2001
- 9th April 2002
Astellas Pharma Inc
- 2nd June 2003
- 27th August 2004
BioMarin Pharmaceutical Inc
- 23rd November 2004
- 5th May 2005
BioMimetic Pharmaceuticals Inc (BMP)
- 8th January 2004
Biota Holdings Limited
- 3rd October 2003
Boehringer Ingelheim
Cyclacel Limited
- 5th December 2003
Eli Lilly
- 20th December 2000
Forest Laboratories Inc
- 12th December 2001
GelTex Pharmaceuticals Inc
- 23rd December 1999
GlaxoSmithKline
- 2nd November 2001
- 27th January 2003
Kissei Pharmaceutical Co Ltd
- 14th March 2001
Kureha Chemical Industry Co Ltd
- March 2001
Kyoto Pharmaceutical Industries Ltd
Metabasis Therapeutics Inc
- 18th December 1997
- 11th January 1999
- 29th October 2002
- 8th April 2004
Novartis
- 8th October 2003
Pfizer
- 18th May 1999
- 29th May 2000
Pharmacopeia Inc
- 3rd February 2003
- 2nd December 2003
Roche
- 10th November 2003
sanofi-aventis
- July 1993
- 13th February 2003
- 5th July 2005
Sanwa Kagaku Kenkyusho
- 9th January 2004
Schering-Plough
- 4th August 2005
Suntory Ltd
- 19th March 2002
Teikoku Hormone Mfg Co Ltd
- 11th December 2000
Ube Industries Ltd
University of Alabama
Zeria Pharmaceutical Co Ltd
- 1st April 2003